MX387318B - Moduladores de la proteólisis basados en imida y métodos de uso asociados. - Google Patents

Moduladores de la proteólisis basados en imida y métodos de uso asociados.

Info

Publication number
MX387318B
MX387318B MX2016013563A MX2016013563A MX387318B MX 387318 B MX387318 B MX 387318B MX 2016013563 A MX2016013563 A MX 2016013563A MX 2016013563 A MX2016013563 A MX 2016013563A MX 387318 B MX387318 B MX 387318B
Authority
MX
Mexico
Prior art keywords
compounds
imide
modulators
binds
inhibition
Prior art date
Application number
MX2016013563A
Other languages
English (en)
Spanish (es)
Other versions
MX2016013563A (es
Inventor
Andrew P Crew
Craig Crews
Hanqing Dong
Jing Wang
Meizhong Jin
Yimin Qian
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of MX2016013563A publication Critical patent/MX2016013563A/es
Publication of MX387318B publication Critical patent/MX387318B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01031—6-Phosphogluconolactonase (3.1.1.31)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
MX2016013563A 2014-04-14 2015-04-14 Moduladores de la proteólisis basados en imida y métodos de uso asociados. MX387318B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461979351P 2014-04-14 2014-04-14
PCT/US2015/025813 WO2015160845A2 (en) 2014-04-14 2015-04-14 Imide-based modulators of proteolysis and associated methods of use

Publications (2)

Publication Number Publication Date
MX2016013563A MX2016013563A (es) 2017-05-09
MX387318B true MX387318B (es) 2025-03-18

Family

ID=54264534

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013563A MX387318B (es) 2014-04-14 2015-04-14 Moduladores de la proteólisis basados en imida y métodos de uso asociados.
MX2021012926A MX2021012926A (es) 2014-04-14 2016-10-14 Moduladores de la proteolisis basados en imida y metodos de uso asociados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012926A MX2021012926A (es) 2014-04-14 2016-10-14 Moduladores de la proteolisis basados en imida y metodos de uso asociados.

Country Status (10)

Country Link
US (2) US20150291562A1 (enExample)
EP (2) EP4649963A2 (enExample)
JP (4) JP6778114B2 (enExample)
KR (6) KR20250127179A (enExample)
CN (2) CN106458993B (enExample)
AU (4) AU2015247817C1 (enExample)
CA (1) CA2945975C (enExample)
MX (2) MX387318B (enExample)
RU (2) RU2738833C9 (enExample)
WO (1) WO2015160845A2 (enExample)

Families Citing this family (337)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107445940A (zh) 2006-09-26 2017-12-08 细胞基因公司 作为抗肿瘤剂的5‑取代的喹唑酮衍生物
KR100987051B1 (ko) * 2008-12-23 2010-10-11 한국수력원자력 주식회사 입자추적법을 이용한 복잡흐름장에서의 오염 물질 이동 수치모사 방법
UA113512C2 (xx) 2011-03-11 2017-02-10 Тверда форма 3-(5-аміно-2-метил-4-оксо-4h-хіназолін-3-іл)піперидин-2,6-діону і її фармацевтична композиція та застосування
EP3608317A1 (en) 2012-01-12 2020-02-12 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2014039421A1 (en) 2012-09-04 2014-03-13 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US9962452B2 (en) 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
CN105518018B (zh) 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
KR20250127179A (ko) * 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
WO2015200837A1 (en) 2014-06-27 2015-12-30 Fl Therapeutics Llc Abiraterone derivatives and non-covalent complexes with albumin
AU2015292710A1 (en) 2014-07-22 2017-02-16 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US10201617B2 (en) 2014-10-24 2019-02-12 Zhuhai Beihai Biotech Co., Ltd. 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR102564925B1 (ko) 2015-01-20 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
CA2988414C (en) * 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP3302482A4 (en) * 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20170008904A1 (en) * 2015-07-10 2017-01-12 Arvinas, Inc. Mdm2-based modulators of proteolysis and associated methods of use
WO2017024319A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
EP3337476A4 (en) * 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
EP3341007B1 (en) 2015-08-28 2020-12-23 Cornell University Malt1 inhibitors and uses thereof
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
RU2018120330A (ru) 2015-11-02 2019-12-04 Йейл Юниверсити Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения
WO2017117474A1 (en) * 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2017117473A1 (en) * 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional molescules for her3 degradation and methods of use
CA3014644A1 (en) 2016-02-15 2017-08-24 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
CN113788818A (zh) * 2016-04-06 2021-12-14 密执安大学评议会 Mdm2蛋白质降解剂
RU2752677C2 (ru) * 2016-04-12 2021-07-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка вет
EP3445452A4 (en) * 2016-04-21 2019-10-30 BioVentures, LLC COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF
AU2017254711B2 (en) * 2016-04-22 2021-01-21 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use
AU2017254702B2 (en) * 2016-04-22 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
JP6968823B2 (ja) * 2016-04-22 2021-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｅｇｆｒの分解のための二官能性分子、及び使用方法
US10865204B2 (en) 2016-04-22 2020-12-15 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
CA3024556A1 (en) 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
GB201610156D0 (en) 2016-06-10 2016-07-27 Otsuka Pharma Co Ltd Cliptac compositions
CA3025806C (en) 2016-06-23 2023-04-04 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
US10702504B2 (en) 2016-06-23 2020-07-07 Dana-Farber Cancer Institute, Inc. Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use
GB201614134D0 (en) * 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2018052949A1 (en) * 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
WO2018052945A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules
WO2018053354A1 (en) 2016-09-15 2018-03-22 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
HUE061847T2 (hu) 2016-10-11 2023-08-28 Arvinas Operations Inc Androgén receptor célzott degradálására alkalmas vegyületek és eljárások
US11331380B2 (en) 2016-10-20 2022-05-17 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
WO2018074563A1 (ja) * 2016-10-21 2018-04-26 学校法人 慶應義塾 フェニルフタルイミド修飾体及びそれを有効成分とする医薬組成物
MX2019004950A (es) 2016-10-28 2019-09-26 Icahn School Med Mount Sinai Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
CA3042260C (en) * 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
US10689366B2 (en) 2016-11-01 2020-06-23 Cornell University Compounds for MALT1 degredation
CA3042297A1 (en) * 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CA3042301A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
CA3045037A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
WO2018118598A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
JP2020505327A (ja) * 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
CN110741004B (zh) 2016-12-23 2023-10-17 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) * 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN107056772A (zh) * 2017-01-23 2017-08-18 中国药科大学 基于cereblon配体诱导BET降解的双功能分子及其制备和应用
AU2018211975B2 (en) * 2017-01-26 2022-05-26 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
KR102747905B1 (ko) * 2017-01-31 2024-12-31 아비나스 오퍼레이션스, 인코포레이티드 세레블론 리간드 및 이를 포함하는 이작용성 화합물
JP7227912B2 (ja) 2017-02-08 2023-02-24 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド キメラ抗原受容体の調節
ES2899372T3 (es) * 2017-02-13 2022-03-11 Kangpu Biopharmaceuticals Ltd Combinación de tratamiento del cáncer de próstata, composición farmacéutica y método de tratamiento
CN110573507B (zh) * 2017-04-14 2023-11-14 邓迪大学 小分子
CN107033147B (zh) * 2017-04-25 2018-08-21 东南大学 一种bet/hdac双靶点抑制剂及其制备方法和应用
CN110545853A (zh) 2017-04-28 2019-12-06 石英治疗有限公司 Raf降解偶联化合物
CN108947888B (zh) * 2017-05-23 2021-05-07 南京理工大学 一种在水相中钯催化合成3-取代异吲哚啉酮的方法
CN110769822A (zh) * 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US10716858B2 (en) 2017-06-30 2020-07-21 Massachusetts Institute Of Technology Branched multi-functional macromonomers and uses thereof
GB201710620D0 (en) * 2017-07-03 2017-08-16 Glaxosmithkline Intellectual Property Ltd Targeted protein degradation
EP3652329B1 (en) * 2017-07-12 2023-10-04 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
BR112020001825A2 (pt) * 2017-07-28 2020-07-21 Arvinas Operations, Inc. compostos e métodos para a degradação direcionada de receptor de androgênio
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN109422733A (zh) * 2017-09-03 2019-03-05 上海美志医药科技有限公司 一类抑制并降解酪氨酸蛋白激酶alk的化合物
CN109422751B (zh) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
IL322809A (en) 2017-09-22 2025-10-01 Kymera Therapeutics Inc Protein Decomposers and Their Uses
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL321733A (en) * 2017-10-18 2025-08-01 Novartis Ag Compositions and methods for selective degradation of proteins
US11505560B2 (en) * 2017-10-20 2022-11-22 Dana-Farber Cancer Institute, Inc. Heterobifunctional compounds with improved specificity
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
US11110177B2 (en) 2017-11-10 2021-09-07 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
US11065231B2 (en) * 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019109415A1 (zh) * 2017-12-04 2019-06-13 清华大学 一种靶向降解hmgcr的化合物及其应用
EP3724180B1 (en) 2017-12-13 2023-02-22 Dana-Farber Cancer Institute, Inc. Compounds for the degradation of stk4 and treatment of hematologic malignancies
AU2018382122B2 (en) * 2017-12-13 2021-11-18 Shanghaitech University ALK protein degradation agent and anti-tumor application thereof
CN111491933A (zh) 2017-12-18 2020-08-04 豪夫迈·罗氏有限公司 具有e3泛素连接酶部分的egfr双功能抑制剂
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN119792569A (zh) * 2018-01-10 2025-04-11 财团法人生物技术开发中心 抗体protac偶联物
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
EP3743066A4 (en) 2018-01-26 2021-09-08 Yale University IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE
TW201945357A (zh) 2018-02-05 2019-12-01 瑞士商赫孚孟拉羅股份公司 化合物
CA3090414A1 (en) * 2018-02-23 2019-08-29 Lei Wu Small molecules that block proteasome-associated ubiquitin receptor rpn13 function and uses thereof
JP2021515013A (ja) 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
CN110240629B (zh) 2018-03-09 2023-10-03 上海科技大学 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
US11028088B2 (en) 2018-03-10 2021-06-08 Yale University Modulators of BTK proteolysis and methods of use
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CN110317192A (zh) * 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物
EP3774789B1 (en) * 2018-04-01 2025-03-05 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
AU2019251151B2 (en) * 2018-04-09 2022-07-07 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
WO2019199816A1 (en) * 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2019200367A1 (en) 2018-04-13 2019-10-17 Massachusetts Institute Of Technology Brush prodrugs and uses thereof
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
EP3556760A1 (en) 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
WO2019201123A1 (zh) * 2018-04-20 2019-10-24 四川科伦博泰生物医药股份有限公司 一种多功能化合物、其制备方法及其在医药上的应用
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
CA3103185A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
WO2019246570A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
KR20210025061A (ko) * 2018-06-29 2021-03-08 다나-파버 캔서 인스티튜트 인크. 세레블론(crbn)에 대한 리간드
WO2020007322A1 (zh) * 2018-07-04 2020-01-09 清华大学 一种靶向降解bet蛋白的化合物及其应用
CN108794453A (zh) * 2018-07-05 2018-11-13 清华大学 一种靶向降解fak蛋白的化合物及其应用
JP2021529807A (ja) * 2018-07-05 2021-11-04 アイカーン スクール オブ メディスン アット マウント シナイ タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
EP3820573B1 (en) 2018-07-10 2023-08-09 Novartis AG 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PE20210184A1 (es) * 2018-07-11 2021-02-02 H Lee Moffitt Cancer Ct & Res Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon
US12011432B2 (en) 2018-07-18 2024-06-18 Case Western Reserve University Method of modulating ribonucleotide reductase
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
EP3841098A4 (en) * 2018-08-22 2022-05-04 Cullgen (Shanghai), Inc. TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHOD OF USE
EP3846800A4 (en) 2018-09-04 2022-08-24 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
CN119219628A (zh) 2018-09-07 2024-12-31 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
DK3897636T3 (da) 2018-12-19 2025-01-13 Celgene Corp Substituerede 3-((3-aminophenyl)amino)piperidin-2,6-dionforbindelser, sammensætninger heraf og fremgangsmåde til behandling hermed
KR102864064B1 (ko) 2018-12-19 2025-09-24 셀진 코포레이션 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
US20220081435A1 (en) * 2019-01-03 2022-03-17 The Regents Of The University Of Michigan Androgen receptor protein degraders
EP3917916A4 (en) * 2019-01-30 2022-12-14 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
WO2020156017A1 (zh) * 2019-02-02 2020-08-06 石药集团中奇制药技术（石家庄）有限公司 靶向泛素化降解brd4蛋白化合物及其制备方法和应用
US20220098196A1 (en) * 2019-02-05 2022-03-31 The Board Of Regents Of The University Of Texas System Trapping-free parp inhibitors
WO2020162725A1 (ko) * 2019-02-07 2020-08-13 한국화학연구원 표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물
US20220143002A1 (en) * 2019-02-25 2022-05-12 Shanghaitech University Sulfur-containing compound based on glutarimide skeleton and application thereof
US11389438B2 (en) * 2019-02-25 2022-07-19 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
CA3131804A1 (en) 2019-03-01 2020-09-10 Ontario Institute For Cancer Research (Oicr) Amide-based proteolysis modulators of b-rapidly accelerated fibrosarcoma (braf) and associated uses
CN113557235B (zh) 2019-03-06 2025-08-08 C4医药公司 用于药物治疗的杂环化合物
CN113939300A (zh) 2019-04-05 2022-01-14 凯麦拉医疗公司 Stat降解剂和其用途
WO2020210337A1 (en) * 2019-04-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
EA202192738A1 (ru) 2019-04-12 2022-03-17 С4 Терапьютикс, Инк. Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
WO2020214555A1 (en) 2019-04-16 2020-10-22 Northwestern University Bifunctional compounds comprising apcin-a and their use in the treatment of cancer
CN119504751B (zh) * 2019-04-18 2025-11-14 海创药业股份有限公司 一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途
CN118908962A (zh) 2019-05-06 2024-11-08 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
JP7426124B2 (ja) * 2019-06-12 2024-02-01 シャンハイテック ユニバーシティ Ａｌｋタンパク質レギュレーター、及びその抗腫瘍における使用
WO2020253711A1 (zh) * 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
CN110372669B (zh) * 2019-06-19 2020-11-24 浙江省医学科学院 一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用
CN114502158A (zh) 2019-06-28 2022-05-13 凯麦拉医疗公司 Irak降解剂及其用途
CN114867727B (zh) 2019-07-17 2025-02-21 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
CA3148504A1 (en) 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
CN114667147B (zh) * 2019-08-26 2024-09-06 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
CA3150653A1 (en) * 2019-09-12 2021-03-18 Yunfu Luo FUSED CYCLIC COMPOUND CAPABLE OF DEGRADING A PROTEIN AND ITS USE
CN110563703B (zh) * 2019-09-18 2021-04-09 浙江省医学科学院 基于crbn配体诱导parp-1降解的化合物及制备方法和应用
US11420956B2 (en) 2019-09-23 2022-08-23 Accutar Biotechnology Inc. Ureas having Androgen Receptor degradation activity and uses thereof
US10836749B1 (en) 2019-09-23 2020-11-17 Accutar Biotechnology Inc. Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
JP7502425B2 (ja) 2019-10-01 2024-06-18 アルヴィナス・オペレーションズ・インコーポレイテッド Ｂｒｍ標的化化合物および関連使用方法
AU2020368453A1 (en) 2019-10-16 2022-04-21 Massachusetts Institute Of Technology Brush prodrugs and uses thereof
EP4045496A1 (en) 2019-10-17 2022-08-24 Arvinas Operations, Inc. Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
IL292359A (en) * 2019-10-22 2022-06-01 Arvinas Operations Inc Prostate cancer treatment methods
WO2021078301A1 (zh) * 2019-10-24 2021-04-29 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
CN110713480B (zh) * 2019-10-28 2021-02-26 浙江省医学科学院 AChE蛋白降解物及其制备方法和应用
CN110790750B (zh) * 2019-11-07 2021-09-21 郑州大学 一种邻苯二甲酰亚胺类选择性雄激素受体降解剂及其制备方法和用途
CN110746400B (zh) * 2019-11-07 2021-12-17 郑州大学 一种靶向雄激素受体的荧光探针及其制备方法
ES3041635T3 (en) 2019-12-16 2025-11-13 Beijing Tide Pharmaceutical Co Ltd Macrocyclic compounds for inhibiting and inducing degradation of egfr kinase in the treatment of cancer
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
EP4076530A4 (en) * 2019-12-17 2024-04-10 Orionis Biosciences, Inc. BIFUNCTIONAL AGENTS FOR RECRUITMENT AND/OR DEGRADATION OF PROTEINS
PH12022551486A1 (en) 2019-12-19 2023-11-13 Arvinas Operations Inc Compounds and methods for the targeted degradation of androgen receptor
MX2022007659A (es) 2019-12-20 2022-07-19 C4 Therapeutics Inc Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr).
CN113087704B (zh) 2019-12-23 2023-09-08 上海济煜医药科技有限公司 一种蛋白降解剂化合物的制备方法和应用
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
AU2021206273A1 (en) * 2020-01-08 2022-07-28 The Brigham And Women’S Hospital, Inc. Multi-functional chimeric molecules
US12042513B2 (en) * 2020-01-10 2024-07-23 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof
EP4097138A4 (en) 2020-01-31 2024-03-13 Avilar Therapeutics, Inc. ASGPR-BINDING COMPOUNDS FOR DEGRADATION OF EXTRACELLULAR PROTEINS
CN113248484A (zh) * 2020-02-13 2021-08-13 上海强睿生物科技有限公司 一种特异性降解tau蛋白的小分子化合物及其应用
WO2021162493A1 (ko) * 2020-02-14 2021-08-19 보로노이 주식회사 단백질 키나아제 분해 유도 화합물 및 이의 용도
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
CN115697989B (zh) * 2020-02-26 2025-03-18 上海睿跃生物科技有限公司 原肌球蛋白受体激酶(trk)降解化合物和使用方法
CN115279370B (zh) 2020-03-05 2025-01-10 C4医药公司 用于brd9的靶向降解的化合物
CN113387930B (zh) * 2020-03-11 2022-07-12 苏州开拓药业股份有限公司 一种双官能化合物及其制备方法和用途
CN115380026B (zh) * 2020-03-17 2023-11-07 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
PH12022552458A1 (en) 2020-03-19 2024-01-22 Kymera Therapeutics Inc Mdm2 degraders and uses thereof
KR102624481B1 (ko) * 2020-03-20 2024-01-16 (주)프레이저테라퓨틱스 p38 제거능을 갖는 화합물, 이의 제조방법 및 이를 포함하는 만성 염증성 질환 치료용 조성물
WO2021194878A1 (en) 2020-03-21 2021-09-30 Arvinas Operations, Inc. Selective modulators of mutant lrrk2 proteolysis and associated methods of use
EP4121422A1 (en) 2020-03-21 2023-01-25 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
KR20210122163A (ko) 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
JP2023521698A (ja) 2020-04-06 2023-05-25 アルヴィナス・オペレーションズ・インコーポレイテッド Ｋｒａｓの標的化分解のための化合物及び方法
US11358992B2 (en) * 2020-04-17 2022-06-14 Uppthera Cell-penetrating cereblon recombinant fusion protein and use thereof
IL297486A (en) * 2020-04-23 2022-12-01 Univ Iowa Res Found Gper proteolytic targeting chimeras
US20230234938A1 (en) * 2020-04-28 2023-07-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2021219077A1 (zh) * 2020-04-29 2021-11-04 泰比棣医药科技(石家庄)有限公司 一种组织靶向的蛋白靶向降解化合物及其用途
CN113582974B (zh) * 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
AU2021273458A1 (en) 2020-05-09 2022-12-01 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CR20230007A (es) 2020-06-12 2023-06-01 Shanghai Jemincare Pharmaceuticals Co Ltd Compuesto de ftalazinona, y método de preparación y uso médico de este.
US12415799B2 (en) * 2020-06-28 2025-09-16 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Indazole-fused cyclic compound
CN114341128B (zh) * 2020-07-24 2024-06-25 恩瑞生物医药科技（上海）有限公司 双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
WO2022032026A1 (en) 2020-08-05 2022-02-10 C4 Therapeutics, Inc. Compounds for targeted degradation of ret
CN114057770B (zh) * 2020-08-06 2023-05-02 成都先导药物开发股份有限公司 靶向egfr蛋白降解的双功能化合物
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN114163444B (zh) * 2020-09-11 2023-07-14 江苏恒瑞医药股份有限公司 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
CR20230162A (es) 2020-09-14 2023-06-02 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
AU2021361044A1 (en) * 2020-10-14 2023-06-08 C4 Therapeutics, Inc. Tricyclic heterobifunctional compounds for degradation of targeted proteins
WO2022087125A1 (en) 2020-10-21 2022-04-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor protein
EP4240733A1 (en) 2020-11-06 2023-09-13 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
CN112341436A (zh) * 2020-11-20 2021-02-09 中国药科大学 基于靶向抑制和降解alk的苯并咔唑类蛋白水解靶向嵌合分子、制备方法及用途
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
TW202237095A (zh) 2020-12-03 2022-10-01 德商艾斯巴赫生物有限公司 Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性
CN112480081B (zh) * 2020-12-07 2022-02-22 沈阳药科大学 一种基于Cereblon配体诱导SHP2蛋白降解的双功能分子化合物
JP2024500377A (ja) * 2020-12-14 2024-01-09 バイオセリックス， インコーポレイテッド Ｐｄｅ４分解剤、医薬組成物、及び治療的応用
JP7434265B2 (ja) * 2020-12-30 2024-02-20 財團法人工業技術研究院 アンドロゲン受容体結合分子およびその使用
WO2022146151A1 (en) * 2020-12-30 2022-07-07 Captor Therapeutics S.A. Novel compounds which bind to cereblon, and methods of use thereof
MX2023007852A (es) 2020-12-30 2023-07-07 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
EP4277901A1 (en) 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
EP4291187A4 (en) 2021-02-15 2025-01-15 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
PE20240235A1 (es) 2021-02-15 2024-02-16 Astellas Pharma Inc Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d
AU2022220869A1 (en) 2021-02-15 2023-08-24 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
EP4308557A1 (en) * 2021-03-19 2024-01-24 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
US20250099596A1 (en) * 2021-03-29 2025-03-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine
AU2022259683A1 (en) 2021-04-16 2023-10-19 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
JP2024517812A (ja) 2021-05-03 2024-04-23 アヴィラー セラピューティクス インコーポレイテッド 免疫グロブリン及びその他のタンパク質を分解する強力なａｓｇｐｒ結合性化合物
IL308219A (en) 2021-05-05 2024-01-01 Biogen Ma Inc Compounds to Target Broton Tyrosine Kinase Degradation
CN117715904A (zh) 2021-05-07 2024-03-15 凯麦拉医疗公司 Cdk2降解剂和其用途
EP4351583A4 (en) 2021-06-08 2025-06-04 C4 Therapeutics, Inc. THERAPEUTICS TO DEGRADE MUTANT BRAF
WO2022266258A1 (en) 2021-06-15 2022-12-22 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
CN113481289B (zh) * 2021-06-22 2022-03-29 天津见康华美医学诊断技术有限公司 一种铁粒幼红细胞性贫血检测引物组合物及应用
CN113354619B (zh) * 2021-06-24 2024-03-19 皖南医学院 一种靶向泛素化降解酪氨酸酶的化合物及其制备方法和应用
KR20240029062A (ko) 2021-07-02 2024-03-05 메르크 파텐트 게엠베하 항-protac 항체 및 복합체
US20250129047A1 (en) 2021-07-04 2025-04-24 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
IL309941A (en) 2021-07-07 2024-03-01 Biogen Ma Inc Compounds to target degradation of IRAK4 proteins
US20250018046A1 (en) 2021-07-07 2025-01-16 Biogen Ma Inc Compounds for targeting degradation of irak4 proteins
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
US20240353397A1 (en) * 2021-08-12 2024-10-24 Ramot At Tel-Aviv University Ltd. Markers of resistance and disease tolerance and uses thereof
EP4367118B1 (en) 2021-08-18 2025-01-29 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
EP4395549A1 (en) 2021-09-01 2024-07-10 Oerth Bio LLC Compositions and methods for targeted degradation of proteins in a plant cell
CN115772210A (zh) * 2021-09-08 2023-03-10 苏州开拓药业股份有限公司 硫代乙内酰脲化合物或其药用盐的无定形物、晶体、药物组合物、制备方法和用途
WO2023038500A1 (ko) * 2021-09-13 2023-03-16 주식회사 유빅스테라퓨틱스 Enl 단백질 분해용 화합물 및 이들의 의약 용도
WO2023056443A1 (en) * 2021-10-01 2023-04-06 Dana-Farber Cancer Institute, Inc. Binders of cereblon and methods of use thereof
AU2022378463A1 (en) 2021-10-25 2024-05-09 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023074780A1 (ja) * 2021-10-27 2023-05-04 国立大学法人愛媛大学 治療薬組成物
EP4422635A4 (en) 2021-10-29 2025-11-26 Kymera Therapeutics Inc IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
CN118679160A (zh) 2021-11-24 2024-09-20 阿维纳斯运营公司 Brm靶向化合物和相关的使用方法
CN118574827A (zh) 2021-11-24 2024-08-30 阿维纳斯运营公司 Brm靶向化合物和相关的使用方法
AU2022397695A1 (en) 2021-11-25 2024-06-06 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Chimeric compound for targeted degradation of androgen receptor protein, preparation method therefor, and medical use thereof
WO2023121753A1 (en) 2021-12-20 2023-06-29 Massachusetts Institute Of Technology Biomolecule-polymer-pharmaceutical agent conjugates for delivering the pharmaceutical agent
WO2023119677A1 (en) 2021-12-24 2023-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
CN114410773B (zh) * 2022-01-27 2024-05-03 宁波大学 用于预测或诊断抑郁症复发的标志物组合及其应用
AU2023214044A1 (en) 2022-01-31 2024-08-08 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN114907386B (zh) * 2022-03-11 2023-03-31 山东大学 一种hemtac小分子降解剂及其应用
CA3255513A1 (en) 2022-03-11 2025-03-04 Astellas Pharma Inc. HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
CN114560908B (zh) * 2022-03-11 2024-10-25 国家纳米科学中心 一种多肽protac分子及其制备方法和应用
CN116789636A (zh) * 2022-03-14 2023-09-22 北京康辰药业股份有限公司 双功能化合物及其制备方法、药物组合物和用途
EP4499628A1 (en) 2022-03-24 2025-02-05 GlaxoSmithKline Intellectual Property Development Limited 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs
EP4518862A1 (en) 2022-05-02 2025-03-12 Eisbach Bio GmbH Use of alc1 inhibitors and synergy with parpi
WO2023230059A1 (en) * 2022-05-24 2023-11-30 Newave Pharmaceutical Inc. Mdm2 degrader
KR20250021314A (ko) 2022-06-06 2025-02-12 씨4 테라퓨틱스, 인코포레이티드 비시클릭-치환된 글루타르이미드 세레블론 결합제
JP2025521686A (ja) 2022-06-27 2025-07-10 リレー セラピューティクス， インコーポレイテッド エストロゲン受容体アルファ分解剤及びその使用
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
CN119487035A (zh) * 2022-06-30 2025-02-18 安宏生医股份有限公司 双官能基化合物及包含所述双官能基化合物的医药组合物及其用于治疗雄激素受体相关疾病的方法
AR129976A1 (es) 2022-07-21 2024-10-16 Astellas Pharma Inc Compuestos heterocíclicos que actúan sobre la proteína kras mutante g12d
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
EP4565236A1 (en) * 2022-08-02 2025-06-11 Beijing Neox Biotech Limited Bcl-xl degrading compounds
AR130126A1 (es) 2022-08-05 2024-11-06 Astellas Pharma Inc Compuesto heterocíclico para inducir la degradación de la proteína kras mutante
WO2024035780A1 (en) * 2022-08-09 2024-02-15 Board Of Regents Of The University Of Nebraska Akr1c3 targeted heterobifunctional small molecule proteolysis targeting chimeras
WO2024034593A1 (ja) 2022-08-09 2024-02-15 アステラス製薬株式会社 Ｇ１２ｖ変異ｋｒａｓタンパクの分解を誘導するための複素環化合物
TW202412809A (zh) 2022-08-12 2024-04-01 日商安斯泰來製藥股份有限公司 包含標靶療法的抗癌組合
TW202410899A (zh) 2022-08-12 2024-03-16 日商安斯泰來製藥股份有限公司 抗癌組合之化學療法
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024054954A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
EP4596538A4 (en) * 2022-09-29 2025-12-31 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF TETRAHYDRONAPHTALENE DERIVATIVE, AND PROCESS OF PREPARATION
CN117801051A (zh) * 2022-09-30 2024-04-02 苏州德亘生物医药有限公司 一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
KR20250079173A (ko) 2022-10-03 2025-06-04 고리츠다이가쿠호진 요코하마시리츠다이가쿠 이환성 구조를 갖는 이미다조피리딘 유도체
EP4428134A1 (en) 2023-03-10 2024-09-11 Dark Blue Therapeutics Ltd Protac degraders of mllt1 and/or mllt3
AU2023416471A1 (en) 2022-12-27 2025-08-07 Merck Patent Gmbh Vhh anti-protac antibodies and complexes
WO2024151557A1 (en) 2023-01-09 2024-07-18 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
JPWO2024150815A1 (enExample) 2023-01-12 2024-07-18
KR20250136883A (ko) 2023-01-24 2025-09-16 다이이찌 산쿄 가부시키가이샤 치환 벤젠 화합물
EP4655073A2 (en) 2023-01-26 2025-12-03 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto
WO2024178348A2 (en) * 2023-02-24 2024-08-29 Ppm Biopharma Llc Pleiotropic pathway modifier compounds and method of treating diseases
CN116854667A (zh) * 2023-05-17 2023-10-10 浙江工业大学 一种靶向降解pd-l1的蛋白水解靶向嵌合体及其应用
KR20240166948A (ko) * 2023-05-18 2024-11-26 아주대학교산학협력단 골 분화 유도 가능한 신규 화합물
WO2024240078A1 (en) * 2023-05-19 2024-11-28 The Chinese University Of Hong Kong Compositions and methods related to protein labeling
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
AR133028A1 (es) 2023-06-22 2025-08-20 Astellas Pharma Inc Composición farmacéutica que comprende un degradador de todas las kras
AR133027A1 (es) 2023-06-22 2025-08-20 Astellas Pharma Inc Composición farmacéutica que comprende un compuesto de quinazolina
WO2025006783A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras
WO2025007000A1 (en) 2023-06-30 2025-01-02 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
GB202314126D0 (en) 2023-09-15 2023-11-01 Univ Oxford Innovation Ltd Compound and method
TW202523291A (zh) 2023-11-02 2025-06-16 美商金橘生物科技公司 降解劑及其用途
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025137500A1 (en) 2023-12-21 2025-06-26 Dana-Farber Cancer Institute, Inc. Kinase inhibition and degradation
WO2025184594A1 (en) 2024-02-29 2025-09-04 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
WO2025213104A1 (en) 2024-04-05 2025-10-09 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of bcl6
CN118161490B (zh) * 2024-05-10 2024-07-23 昆明医科大学 一种去泛素化酶抑制剂在制备预防或者治疗炎症药物中的应用
EP4667467A1 (en) 2024-06-21 2025-12-24 Dark Blue Therapeutics Ltd Protac degraders of mllt1 and/or mllt3
EP4667466A1 (en) 2024-06-21 2025-12-24 Dark Blue Therapeutics Ltd Protac degraders of mllt1 and/or mllt3
CN118459478B (zh) * 2024-07-09 2024-10-29 深圳大学 一种brd4蛋白靶向降解剂及其制备方法与应用
CN120154610B (zh) * 2025-05-19 2025-09-02 深圳大学 抗血栓小分子化合物bptu作为黏菌素佐剂协同抗革兰氏阴性菌的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CZ302378B6 (cs) * 1996-07-24 2011-04-20 Celgene Corporation Optický izomer (S)-1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin a farmaceutická kompozice s jeho obsahem
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7320991B2 (en) * 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
CN100383139C (zh) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
FR2885904B1 (fr) * 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
CA2822094C (en) * 2005-08-31 2015-10-27 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
RU2448101C2 (ru) * 2006-08-30 2012-04-20 Селджин Корпорейшн 5-замещенные изоиндолиновые соединения
JP5523831B2 (ja) * 2006-08-30 2014-06-18 セルジーン コーポレイション ５−置換イソインドリン化合物
EP3354646A1 (en) * 2008-10-29 2018-08-01 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
EP2453908B1 (en) * 2009-07-13 2018-03-14 President and Fellows of Harvard College Bifunctional stapled polypeptides and uses thereof
SG10201501062SA (en) * 2010-02-11 2015-04-29 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
US8981083B2 (en) * 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
CN103068812A (zh) * 2010-06-09 2013-04-24 基因里克斯(英国)有限公司 沙利度胺晶型及其制备方法
AU2011305315A1 (en) * 2010-09-24 2013-03-28 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS
US20140243282A1 (en) * 2010-12-31 2014-08-28 Satish Reddy Kallam Methods and compositions for designing novel conjugate therapeutics
US9365640B2 (en) * 2011-04-29 2016-06-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP3608317A1 (en) * 2012-01-12 2020-02-12 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
KR20250127179A (ko) * 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
EP3302482A4 (en) * 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
HUE061847T2 (hu) * 2016-10-11 2023-08-28 Arvinas Operations Inc Androgén receptor célzott degradálására alkalmas vegyületek és eljárások

Also Published As

Publication number Publication date
AU2019240589A1 (en) 2019-10-24
KR102320082B1 (ko) 2021-10-29
MX2021012926A (es) 2021-11-17
EP3131588A4 (en) 2018-01-10
KR20200097827A (ko) 2020-08-19
CN106458993B (zh) 2025-08-29
BR112016024016A2 (pt) 2018-01-23
JP6778114B2 (ja) 2020-10-28
RU2020139890A (ru) 2022-01-18
EP3131588B1 (en) 2025-11-05
RU2738833C2 (ru) 2020-12-17
MX2016013563A (es) 2017-05-09
US20220089570A1 (en) 2022-03-24
AU2023285744A1 (en) 2024-01-18
AU2015247817A1 (en) 2016-10-27
CN106458993A (zh) 2017-02-22
RU2016144289A3 (enExample) 2018-05-18
WO2015160845A3 (en) 2015-12-10
AU2019240589B2 (en) 2021-10-21
CA2945975A1 (en) 2015-10-22
JP7169327B2 (ja) 2022-11-10
US20150291562A1 (en) 2015-10-15
CA2945975C (en) 2023-03-14
JP2025020416A (ja) 2025-02-12
EP3131588A2 (en) 2017-02-22
AU2021236430A1 (en) 2021-10-14
KR20170002446A (ko) 2017-01-06
RU2016144289A (ru) 2018-05-18
CN119591582A (zh) 2025-03-11
AU2023285744B2 (en) 2025-11-20
KR20210132233A (ko) 2021-11-03
KR20240038809A (ko) 2024-03-25
EP4649963A2 (en) 2025-11-19
JP2022191517A (ja) 2022-12-27
KR20250127179A (ko) 2025-08-26
AU2015247817B2 (en) 2019-10-31
JP2021008507A (ja) 2021-01-28
AU2015247817C1 (en) 2022-02-10
WO2015160845A2 (en) 2015-10-22
KR20220101015A (ko) 2022-07-18
RU2738833C9 (ru) 2022-02-28
JP2017513862A (ja) 2017-06-01

Similar Documents

Publication Publication Date Title
MX387318B (es) Moduladores de la proteólisis basados en imida y métodos de uso asociados.
MX389264B (es) Moduladores de proteolisis basados en imida y metodos de uso asociados.
MX2021010482A (es) Compuestos y metodos para la degradacion mejorada de proteinas especificas.
MX2018000360A (es) Moduladores basados en mdm2 de proteolisis y metodos de uso asociados.
MX2018000471A (es) Moduladores de proteolisis basados en alanina y metodos de uso asociados.
MX2022009478A (es) Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
WO2018144649A8 (en) Cereblon ligands and bifunctional compounds comprising the same
MX2020010571A (es) Ligandos de cereblon y compuestos bifuncionales que los comprenden.
MX2019007646A (es) Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
MX2019005007A (es) Protac dirigidos a la proteína tau y métodos asociados de uso.
MX2023004018A (es) Moduladores de la proteolisis del receptor de estrogeno y metodos asociados de uso.
BR112017002594A2 (pt) compostos inibidores de cinase de ligação de tank
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
BR112018068702A2 (pt) inibidores bicíclicos em ponte de menin-mll e métodos de uso
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
CL2015002932A1 (es) Inhibidores de proteína quinasa
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
EA201591962A1 (ru) Ингибиторы акк и их применение
MX388753B (es) Complejos no covalentes basados en albúmina y métodos de uso de los mismos.
WO2014144817A3 (en) Inhibitory polypeptides specific to wnt inhibitors
EA201892083A1 (ru) Замещенные ингибиторы менина-mll и способы применения